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Case presentation
The prospective donor was a 17-year-old white female who had
sustained a severe head injury in a motor vehicle accident. By the time
she was brought to the Emergency Room, she had evidence of cerebral
edema and increased intracerebral pressure; she was given intravenous
dexamethasone, 10 mg, and mannitol, 100 ml of a 25% solution.
Intravenous naloxone, 2 mg, was given empirically but had no effect on
her neurologic condition. Surgical exploration of her wounds required
the use of pancuronium, fentanyl, and thiamylal as anesthetic agents. In
addition, she was given 100 mg of phenytoin intramuscularly to prevent
seizures; 1 g of cefazolin intravenously as infection prophylaxis; and
300 mg of cimetidine intravenously to prevent gastric ulcers.
Neurologic examination following her recovery from anesthesia
could not demonstrate a response to painful external stimuli; corneal,
vestibulocular, and gag reflexes were absent; the pupils were fixed; and
neither motor nor cranial nerve responses could be elicited. Electroen-
cephalography revealed no electrocerebral activity. An apnea test
disclosed no spontaneous muscular movement or respiration despite a
rise in the PaCO2 to 60mm Hg. At the conclusion of the test, ventricular
tachycardia was successfully treated with 100 mg of lidocaine intrave-
nously.
Over a 4-hour period, the patient's urine flow averaged 512 mI/hr and
she received an average of 410 mI/hr of 0.9% sodium chloride solution
intravenously. At that time, the blood pressure was 106/62 mm Hg;
pulse, 104 beats/mm; and temperature, 370 C. Laboratory data were:
serum sodium, 155 mEq/liter; potassium, 3.4 mEq/liter; chloride, 124
mEq/liter; bicarbonate, 19 mEq/liter; and glucose, 720 mg/dl. The BUN
was 13 mg/cl! and the serum creatinine 1.2 mg/dl. The hematocrit was
35.7%; white blood cell count, 27,100 mm3; and platelets, 272,000 mm3.
Urinalysis showed a specific gravity of 1.010, a pH of 5.0, and 2+
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glucose. Microscopic examination of the urine disclosed only a rare
white blood cell/high-power field.
The rate of intravenous fluid replacement was increased to 900 mi/hr
of 0.2% sodium chloride solution. Regular insulin, 10 U/liter, was added
to treat the hyperglycemia; potassium chloride, 10 mEq/liter, and
sodium bicarbonate, 44 mEq/liter, were added to treat hypokalemia and
acidosis. Pitressin, 20 U in 500 ml 0.9% sodium chloride solution, was
infused intravenously at approximately 1 mI/mm. Her urine output fell
to 270 mI/hr. A supraventricular tachycardia was treated with vera-
pamil, 5 mg intravenously. Her neurologic condition did not improve;
the diagnosis of brain death was made, and consent was obtained for
donor nephrectomy.
In an attempt to prevent renal vasospasm during the period prior to
nephrectomy, an infusion of prostacyclin (PGI2, epoprostenol) was
started at a dose of 2.0 ng/kg/mmn immediately prior to the surgical
incision. The infusion was maintained for 10 minutes and then increased
in increments of 2 ng/kg/min every 10 minutes until the dose was 8.0
ng/kg/min. The infusion was continued until vascular isolation of the
kidneys was complete. Table 1 contains data pertinent to the P012
infusion.
During the 89-minute treatment period, fluid intake was 3000 ml and
urine output was 490 ml. The fall in blood pressure that occurred with
the PGI2 dose of 6 nglkg/min was treated with an intravenous infusion
of dopamine, 6 gIkg/min. Immediately prior to the donor nephrec-
tomy, an additional intravenous infusion of mannitol, 50 ml of a 25%
solution, was given to maintain urine output. Heparin, 30,000 U, also
was administered.
Following in-situ perfusion, the nephrectomy was accomplished
using the en-bloc technique. Neither kidney was exposed to a period of
warm ischemia. The duration of cold storage was 37 minutes and 48
minutes for the left and right kidneys, respectively. The harvested
kidneys were preserved using the continuous hypothermic perfusion
method. The duration of pulsatile perfusion was 35 hours 24 minutes for
the left kidney and 37 hours 35 minutes for the right kidney. Table 2
shows the characteristics of the perfused kidneys.
The recipient of the left kidney was a 22-year-old black woman with
chronic glomerulonephritis. Her blood pressure was 140/100 mm Hg,
and the pulse was 70 beats/mm. Her pre-transplant BUN was 67 mg/di;
the serum creatinine was 12.5 mgldl. At the time of the anastomosis, the
kidney became distended when the vascular clamps were removed, and
it functioned immediately. lntraoperative urine output was 80 ml over
45 minutes. On the day following transplantation, the BUN was 28
mg/cl!, and the serum creatinine was 4.2 mg/cl!. Over the next 2 days, the
BUN and serum creatinine fell to 16 and 2.6 mg/dl, and 16 and 1.6
mg/dl, respectively. Urinalysis showed a specific gravity of 1.010 and a
pH of 7.5. Microscopic examination disclosed only 6 to 10 red blood
cells/high-power field.
Immunosuppression was achieved with cyclosporine A and intrave-
nous methylprednisolone. Hypertension was controlled by 100 mg of
metoprolol and 0.2 mg of clonidine. The patient also received cephapi-
rin, I g intravenously; cephalexmn, 500 mg orally, and nystatin, 500,000
U in 240 ml of water. Analgesia was obtained with 2 mg of subcutaneous
hydromorphone. Fever was treated with 500 mg of acetaminophen.
Prochlorperazine, 5 mg intramuscularly, controlled her nausea. By the
time of discharge, 8 days after transplantation, the BUN and serum
creatinine were 14 mg/dl and 1.1 mg/dl respectively.
The recipient of the right kidney was a 32-year-old white man with
polycystic kidney disease. His blood pressure was 136/90 mm Hg and
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Table 1. PGI2 infusion in the case presented
Infusion
rate
ng/kg/min
Minutes of
infusion
ArterialDose pressure
ng/kg g mm Hg
Mean
arterial
pressure
mm Hg
Heart
rate
bpm
0
2
4
6
8
—
10
10
10
59
— 123/68
20 0.8 135/88
40 1.6 110/71
60 2.4 106/66
472 18.9 116/79
86
103
84
79
94
98
102
108
122
136
Table 2. Characteristics of the perfused kidneys in the case presented
Time
Perfusate
flow rate
(mI/mm)
Pressure
(mm Hg)
Vascular
resistance
(mm Hg/mi/mm)
Left Right Left Right Left Right
Initial
24—48 hr
Final
100
138
150
80 52/26 52/26
138 45/10 45/10
130 45/10 45/10
0.52
0.24
0.22
0.65
0.24
0.25
his pulse was 92 beats/mm. The pre-transplant BUN was 74 mg/dl and
the serum creatinine 17.5 mg/dl. At the time of the anastomosis, the
kidney was pink, firm, and of normal appearance. The allograft
funtioned immediately posttransplant. Intraoperative urine output was
255 ml in 96 mm. On the day following transplantation, the BUN was 72
mg/dl and the serum creatinine 14.1 mg/dl. Over the next 2 days, the
BUN and serum creatinine fell to 53 and 8.1 mg/dl and 44 and 5.0 mgldl,
respectively. Urinalysis showed a specific gravity of 1.024; a pH of 5.5;
1 + protein; and 3+ blood. Microscopic examination disclosed 25 to 50
white blood cells, more than 50 red blood cells, and rare casts and
bacteria/high-power field.
Immunosuppression was achieved with cyclosporine A and methyl-
prednisolone. In the posttransplant period, he also received 500 mg of
ampicillin, 500 mg of oxacillin, and nystatin, 500,000 U in 240 ml of
water. Pain was controlled by intramuscular meperidine, 50 mg; hy-
droxyzine, 50 mg; acetaminophen, 300 mg; and codeine, 15 mg. The
patient also received oral ranitidine, 150 mg orally.
Discussion
DR. WILLIAM F. FINN (Medical Director, Renal Transplant
Program, and Professor of Medicine, The University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina): The case
presented today describes an attempt to modify the effects of
renal ischemia by the use of prostacyclin, one of the many
agents that lessen renal ischemic injury (Table 3). Those har-
vesting the kidneys from the donor presumed that the relatively
controlled conditions under which the organs were removed
would allow any benefit of the PG!2 infusion to be seen.
Although a favorable outcome was indeed obtained, manage-
ment of the donor required the administration of drugs other
than prostacyclin that have been reported to lessen renal
ischemic injury. For example, the donor received a thiobarbi-
turate as well as verapamil, mannitol, dopamine, and naloxone.
The kidneys were preserved under hypothermic conditions
using perfusion fluids designed to preserve cell viability and
volume. Furthermore, both recipients were treated with alpha-
and beta-adrenergic blocking agents and methyiprednisolone.
! would like to discuss a sampling of the data that support the
concept that one can modify the course of postischemic acute
renal failure by using various pharmacologic agents. Attention
will be directed to the effects of these agents on the ischemic
Table 3. Agents effective in reducing ischemic injury
Adenine nucleotides
Thyroid hormone
Xanthine oxidase inhibitors
Allopurinol
Oxypurinol
Free radical scavengers
Superoxide radicals—Superoxide dismutase
Hydroxyl radicals
Dimethylthiourea
Mannitol
Iron chelators—Deferoxamine
Calcium-channel-blocking agents
Verapamil
Nifedipine
Diltiazem
Prostaglandins
PG!2
PGE1
PGE2
Thromboxane synthetase inhibitors
Atrial natriuretic peptide
Miscellaneous
Thiobarbiturates
Naloxone
Methylprednisolone
injury that occurs in association with renal transplantation. I
will not discuss the use of diuretics, nor will I dwell on agents
used exclusively for their ability to increase renal blood flow.
Rather, I will concentrate on the thesis that the fundamental
concern following an ischemic insult is the extent of tubular
epithelial cell injury and its rate of recovery.
Several observations serve as the basis for this position.
First, our own data indicate that following a 60-minute period of
complete renal artery occlusion in the rat, the immediate cause
of the decline in the glomerular filtration rate is the development
of obstruction to tubular fluid flow [1]. Second, as a result of the
intratubular obstruction, a series of events produces secondary
abnormalities in renal blood flow and in renal vascular resis-
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tance [2, 3]. Third, regeneration of tubular epithelial cells
initiates recovery, and only later does blood flow return to
normal [4].
The importance of the injury to tubular epithelial cells is
further underscored by the inability of many nonspecific vasodi-
lators to prevent injury or promote recovery, and by the
success in minimizing renal injury using agents that do not
increase renal blood flow. I am not saying that we should ignore
abnormalities in renal blood flow, but only that efforts at
directly promoting and preserving cell viability have been much
more successful.
Hypothermia
We have known for more than 60 years that a reduction in
temperature is among the most effective means by which the
kidney can be protected from an ischemic insult [51. In many
respects, hypothermia is the standard by which other maneu-
vers should be measured. Its effectiveness can be attributed to
the decrease in metabolic activity and reduction in the expen-
diture of energy that accompanies a decline in kidney temper-
ature. As renal temperature falls, oxygen consumption drops
exponentially [6—8]. At temperatures of 6° C to 10° C—the
temperature range at which human cadaveric kidneys are
perfused prior to transplantation—metabolism is reduced by
90% to 95% [6].
The activity of a number of enzyme systems is reduced pan
passu with the reduction in temperature. Membrane-bound
enzymes are more affected than are soluble enzymes, appar-
ently because of temperature-induced changes in the physical
state of membrane-bound lipids. A primary example is the
effect on the activity of membrane-bound ion-transport systems
[9—11]. The change in the rate of energy-dependent metabolic
processes is thought to be fundamental to the protection af-
forded by hypothermia. Three examples will suffice. (1) In the
rat, a 60-minute period of complete renal artery occlusion
following a reduction of body temperature to 27° C maintains
the postischemic inulin clearance at a value approximately 40%
of control; this modest decrement compares with the value of
approximately 2% of control in normothermic animals. At the
same time, tubular function is preserved in the hypothermic
animals, as judged by fractional salt and water excretion [12].
(2) In the dog, 3 hours of warm ischemia leads to progressive
azotemia and death over 3 days, whereas a similar period of
cold ischemia produces only minor and transient changes in the
serum creatinine concentration [131. (3) In humans, preserva-
tion of the kidney prior to transplantation by cold storage or by
continuous hypothermic perfusion for approximately 30 or 72
hours, respectively, is not incompatible with immediate graft
function. By contrast, the kidney is no longer viable after a
2-hour period of normothermic perfusion.
Adenine nucleotides
The initial cause of the renal tubular epithelial cell injury that
occurs during ischemia is a reduction in oxygen supply. This
reduction is associated with well-documented alterations in
adenine nucleotide metabolism [14—16], specifically, a rapid
decline in ATP and other high-energy phosphate compounds
[17]. In the rat, a decline in renal cortical ATP concentration
can be detected after a relatively brief period of ischemia. The
extent to which the ATP concentration falls is influenced by the
body temperature and is increased by hyperthermia and de-
creased by hypothermia [18]. Not surprisingly, the rate of
formation of adenine nucleotide degradation products rises [19,
201. In cortical biopsies from human donor kidneys stored on
ice prior to transplantation, one-third of the adenine nucleotide
pool is lost over 25 hours [21].
The decline in ATP levels reflects an imbalance between the
continued utilization of ATP and its regeneration by oxidative
phosphorylation. Warm ischemia effects a rapid loss of mito-
chondrial activity, which eventually involves the enzymes
necessary for the transportation of electrons. With cold isch-
emia, however, mitochondria retain the ability to transport
electrons, albeit at a reduced rate. In this situation, the defect in
the regeneration of ATP appears to result from the reduction in
the movement of adenine nucleotides across the mitochondrial
inner membrane; this decreased flux in turn might be due to
inhibition of the enzyme adenine nucleotide translocase. The
failure of ADP to move into mitochondria could be the rate-
limiting step for ATP synthesis under conditions of hypother-
mia and might be an early event during normothermic ischemia.
Although some investigators have tried to correlate the
extent of ATP loss with kidney viability [22, 23], the relation-
ship is not clear. Renal tubular epithelial cells can tolerate
considerable reductions in ATP availability without manifesting
adverse effects [24]. For example, the hypothermic kidney
remains viable for prolonged periods even with the fall in ATP.
Also, maneuvers that stimulate ATP synthesis do not necessar-
ily increase viability. It would appear that a more important
concern than the absolute level to which ATP levels fall is the
kidney's intrinsic ability to synthesize ATP after the ischemic
insult.
An understanding of the consequences of ATP loss has led to
a number of attempts to remedy the situation. This topic
recently was reviewed in detail by Siegel and Gaudio [25] and
will only be highlighted here. Siegel et al reported that rats that
received ATP-MgC12 immediately after a 30-minute period of
bilateral renal artery occlusion had significantly less functional
impairment and structural abnormalities 24 hours later than did
rats that received saline, Similar results were achieved with the
infusion of ADP-MgC12 or AMP-MgC12 [26]. Although it was
thought initially that the effect was due to renal vasodilation or
the presence of other substances in the test solutions, it has
become apparent that these explanations were not correct.
In this study it was of considerable interest that the ATP-
MgCl2 was effective when given after the period of ischemia.
Indeed, the beneficial effect of treatment with ATP-MgCl2 is
evident even when the infusion is delayed for 8 hours or 24
hours [27]. The salutory effect of ATP-MgC12 appears to be
related to the preservation of sublethally injured cells and
acceleration of the process of restoration and repair of damaged
cells. These studies led Gaudio and coworkers to conclude that
the subsequent improvement found 48 hours after the ischemic
period was related to an enhancement of the rate of recovery
rather than to a limitation of the initial injury [28]. Indeed, this
group has suggested that the effectiveness of ATP is more likely
related to its ability to facilitate resynthesis of the cellular
adenine nucleotide pool than to its capacity as a direct source of
energy [29]. These are but a few of the studies demonstrating
that ATP-MgCl2 administration abrogated some of the impair-
ment of energy metabolism and that an increase in cellular ATP
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content was responsible for preservation and improvement of
renal function.
Thyroid hormone
Similar conclusions have been reached regarding treatment
with thyroid hormones. The thyroid hormones tri-lodothyro-
nine (T3) and thyroxine (T4) participate in growth, develop-
ment, and thermogenesis. They augment protein synthesis,
promote glucose and amino acid uptake by epithelial cells, and
stimulate oxygen consumption. Mitochondria have been con-
sidered a prominent subcellular locus of action of these hor-
mones and, in fact, thyroid hormone can bind to a component of
the inner mitochondrial membrane.
The administration of physiologic doses of T3 increases
oxidative phosphorylation. In addition, the administration ofT3
stimulates the activity of Na/K-ATPase, which in turn stim-
ulates mitochondrial respiration [30, 311. The activity of various
enzymes, including adenine nucleotide translocase, also might
be stimulated by T3. I already have mentioned that this enzyme
promotes the transport of ADP into the mitochondria and ATP
out of the mitochondria into the cytoplasm; inactivity of this
enzyme could be fundamental to the decay in cellular ATP
levels observed with ischemia [321.
A number of interesting observations have been made con-
cerning the effects ofT3 administration both in nephrotoxic and
ischemic forms of experimental acute renal failure. The initial
observations were made in rats given mercuric chloride [33, 341
and later were extended to rats with acute renal failure due to
potassium dichromate administration [35]. The studies by Sie-
gel et al are of particular interest [36]. They examined rats
subjected to 45 minutes of bilateral renal artery occlusion.
Immediately following the ischemic period, the animals re-
ceived either normal saline, 25 imo1 of vanadate-free ATP-
MgCI,, or 50 tg/kg of T4. Twenty-four hours later, the inulin
clearances in the animals given saline were approximately 35%
of control values, whereas in the animals given either ATP-
MgCl, or T4, the values were approximately 60% of control
values. In the animals given either ATP-MgCl2 or T4, the
urinary osmolality and the fractional sodium excretion were
greatly improved when compared with values from saline-
treated control animals. The authors' presumption that tubular
epithelial cell integrity had been maintained was confirmed: in
the treated animals, a significantly greater quantity of inulin
injected directly into the tubules was recovered in the urine.
This finding is consistent with less tubular backleak in the
treated animals. During renal ischemia, ATP levels declined
rapidly to less than 20% of control values, as measured by
nuclear magnetic resonance studies. With reflow, there was an
immediate return to 50% in all groups. Over the next 120
minutes, however, the rise in ATP was significantly increased in
the treated groups [37]. The marked similarity in the responses
to T4 and to ATP-MgCI2 suggests the possibility that similar
mechanisms are responsible for their beneficial effect. On the
one hand, ATP-MgCl2 appears to be supplying precursors for
its own resynthesis; on the other hand, T4 may promote ATP
regeneration by stimulating mitochondrial respiration through
an action on adenyl nucleotide translocase.
I would like to move to a totally different area, but one that
might have some bearing on the relationship of thyroid hormone
and renal ischemic injury. After brain death occurs, the hemo-
dynamic status of the donor can deteriorate. In experimental
animals, brain death is accompanied by a rapid reduction in
circulating T3 and cortisol levels, presumably because of hypo-
thalamic dysfunction [38]. The reduction in T3 levels might be
associated with an increase in anaerobic metabolism with,
among other abnormalities, an accumulation of lactate and free
fatty acids in the plasma [38]. The accumulation of lactate and
free fatty acids can be reversed by the administration of T3,
cortisol, and insulin [39]. After this maneuver, cardiac perfor-
mance after cardiac transplantation is much improved [39].
Others have demonstrated low T3 and T4 in a majority of human
brain-dead organ donors [40], but the relationship of this finding
to hemodynamic deterioration has not been demonstrated [41].
Although these studies are mostly concerned with the results of
thyroid hormone on cardiac function, they are relevant to
today's discussion. That is, it has been observed that there is a
significant reduction in the K :Na ratio of kidney slices
excised from brain-dead pigs. This ratio has been correlated
with renal function and has been used as a marker of parenchy-
mal injury. Notably, the administration of T3, cortisol, and
insulin significantly improved the Na:K ratio [42]. Whether
or not this improvement applies to the function of the renal
allograft has not yet been determined.
Novitzky and colleagues proposed that brain death is accom-
panied by a general inhibition of aerobic metabolism that stems
from a decrease in mitochondrial function and that leads to the
intracellular depletion of ATP and an increase in lactate [43].
The administration of T3, insulin, and cortisol stimulates the
rate of aerobic metabolism. Presumably this is a result of the
action of thyroid on mitochondria and is accompanied by an
increase in Na/K-ATPase activity and improved cell volume
regulation. These changes might explain the decline in func-
tional deterioration observed in kidneys of brain-dead pigs
treated with thyroid hormone, insulin, and cortisol [44].
These studies also are important because various nonthyroi-
dal illnesses can be accompanied by a reduction in serum
concentrations of total T4 and T3. This condition is marked by
abnormalities in peripheral thyroid kinetics and the presence of
a thyroid-hormone-binding inhibitor. Whether or not patients
with nonthyroidal illnesses with low T4 or T3 or both are
hypothyroid is uncertain [45]. Equally uncertain is the possibil-
ity that thyroid administration in these patients prevents the
predisposition to the development of acute renal failure or
promotes early or more complete recovery.
Xanthine oxidase inhibitors
The decrease in cellular ATP levels associated with ischemia
is accompanied by an increase in the dephosphorylated degra-
dation products of adenine nucleotides and the intracellular
accumulation of hypoxanthine. Also, the xanthine oxidase
inhibitor allopurinol is effective in reducing ischemic injury in
laboratory animals [46—50]. Several mechanisms to explain this
effect have been proposed. First, the conversion of hypoxan-
thine to xanthine and uric acid is irreversible, so this reaction
has the potential of removing purine metabolites from the pool
available for the resynthesis of AMP, ADP, and ATP. The
demonstration that the survival of dogs with hemorrhagic shock
can be increased by combined treatment with allopurinol and
hypoxanthine is consistent with the notion that inhibition of
xanthine oxidase minimizes the loss of purine metabolites and
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promotes their reincorporation into AMP, ADP, and ATP [46].
Second, it has been suggested that the rate of decline of ATP
levels could be reduced by xanthine oxidase inhibition to the
extent that the conversion of hypoxanthine to xanthine to uric
acid was the rate-limiting reaction. The observation that higher
concentrations of ATP, ADP, and AMP are maintained in
allopurinol-treated animals during ischemia supports this con-
clusion [46]. Third, xanthine oxidase activity is an important
component of free-radical generation. Hansson et al proposed
that the major benefit of xanthine oxidase inhibition is to
decrease the formation of oxygen-free radicals [48]. In this
regard, they noted that the increase in hypoxanthine concen-
tration during ischemia was followed by an increase in the
xanthine concentration during recirculation, indicating that
oxidation of the hypoxanthine had occurred and suggesting that
oxygen-free radicals had been produced. There is reason for
caution, for in an analysis of human kidneys, Maessen and
coworkers could not identify xanthine as a major degradation
product during nucleotide breakdown one hour following the
onset of reperfusion [211. Fourth, Moorhouse and colleagues
presented evidence that allopurinol is a scavenger of the highly
reactive hydroxyl radical and that oxypurinol is an even better
hydroxyl radical scavenger than is allopurinol [49]. Conse-
quently, the protective actions of allopurinol in the post-
ischemic kidney need not be entirely due to xanthine oxidase
inhibition.
These observations stimulated the use of allopurinol in ex-
perimental renal transplantation. Toledo-Pereyra subjected au-
totranspianted dogs to 40—90 minutes of renal ischemia followed
by 24 hours of hypothermic, pulsatile perfusion [50]. These
investigators demonstrated that allopurinol, when given 100
mg/kg/day by mouth for 4 days preceding and 10 days following
transplantation, with an additional 500 mg/liter added to the
perfusate, protected against ischemic damage. In these studies,
three perfusates were used: cryoprecipitated, pooled dog
plasma, human albumin, and human plasminate. In each group,
treatment with allopurinol prevented irreversible damage and
promoted early recovery. However, a double-blind, random-
ized study of 34 human cadaveric kidneys from 17 consecutive
donors found no effect when allopurinol, 250 mg/liter, was
added to the perfusate of cadaveric kidneys preserved by
pulsatile perfusion prior to transplantation [51]. The authors
found no significant differences in long- or short-term allograft
function, onset of diuresis, return of renal function (defined by
a creatinjne clearance of >5 mi/mm), number of hemodialysis
treatments required, or incidence of ATN.
Free-radical scavengers
A significant portion of the damage sustained by the ischemic
kidney occurs not during the period of ischemia, but rather
during and following reperfusion [52—541. Exposure of the
previously ischemic kidney to molecular oxygen (02) during
reperfusion elicits the production of reactive oxygen radicals.
These free radicals have one or more unpaired electrons in their
outer shells and, as they attempt to restore normal electron
pairing in their orbitals, they interact with other molecules and
produce secondary tissue damage.
Superoxide radical (02) formation results from electron
transfer processes such as those in mitochondria and the
endoplasmic reticulum, from NADPH-requiring enzymes of
macrophages and, as I mentioned, from the action of xanthine
oxidase. Under the influence of superoxide dismutase, two
molecules of 02 form hydrogen peroxide (H202) and 02.
Various peroxidases such as catalase and giutathione peroxi-
dase inactivate H202. In the presence of transition metals such
as iron, however, the highly reactive hydroxyl radical (OW) is
produced from 02 and H202. Superoxide-radical-induced cy-
totoxicity appears largely to depend on the subsequent produc-
tion of 0H. Histidine, tryptophan, ascorbate, and alpha-
tocopherol are natural 0H scavengers. Uric acid can act as an
0H scavenger too, but it also has the capacity to bind iron and
to influence the formation of 0H.
With reperfusion of the previously ischemic kidney, a sudden
increase of free radical activity can overwhelm protective
mechanisms and promote the peroxidation of polyunsaturated
fatty acids in the membranes of cells, mitochondria, and lyso-
somes. In this way, permeability is increased, transport pro-
cesses are altered, and a series of self-perpetutating adverse
events is set into motion. These sometimes involve changes in
intracellular calcium concentration and distribution and abnor-
malities in prostaglandin synthesis.
The data that support a role for free-radical damage in
reperfusion injury of the kidney are accumulating, although
some disagreement exists based on the extreme difficulty one
encounters in measuring the specific reactions under consider-
ation. The work of Paller et al was particularly important in
establishing the notion that free radicals cause renal ischemic
injury [551. These investigators gave 8 mg of superoxide dismu-
tase to uninephrectomized rats before and after 60 minutes of
renal artery occlusion. The plasma creatinine concentration
was lower, and tubular epithelial cell injury was less severe, in
the superoxide-dismutase-treated rats 24, 48, and 72 hours after
the ischemic period. The 0H scavenger dimethylthiourea
(DMTU) and the xanthine oxidase inhibitor allopurinol both
lowered the serum creatinine concentration at 24, 48, and 72
hours.
When lipid peroxidation by free radicals takes place, lipid
substrate is lost, and malondialdehyde, conjugated dienes,
hydroperoxides, and short alkanes such as methane, ethane,
and pentane are formed. In the studies I mentioned, the lipid
peroxide malondialdehyde was increased in renal cortical mito-
chondria following a 15-minute period of reflow. Importantly,
treatment with superoxide dismutase prevented this increase in
malondialdehyde, indicating that the degree of lipid peroxida-
tion had been limited. In other studies, Paller and Hebbel
demonstrated that the increase in ethane in expired gas (which
had been noted to occur during the first 10 minutes of renal
reperfusion) could be prevented by the administration of super-
oxide dismutase or allopurinol [56]. The fact that these inves-
tigators achieved both anatomic and functional improvement
with the use of chemically dissimilar agents, along with de-
creased signs of lipid peroxidation, supplies indirect evidence of
protection from free-radical-mediated injury.
Other investigators have provided complementary data [57—
59]. Baker and coworkers studied uninephrectomized rats fol-
lowing 45 minutes of renal artery occlusion [60]. Seven days
later the survival rate was 56% in controls and 100% in rats
given either superoxide dismutase or allopurinol before reper-
fusion. However, the serum creatinine concentration fell more
slowly with allopurinol than with superoxide dismutase
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pretreatment. This observation suggested that superoxide dis-
mutase was more effective than allopurinol, perhaps because
02 is generated from sources other than those involving the
action of xanthine oxidase.
More recently, Paller and Hedlund found that infusion of the
iron chelator deferoxamine (200 mglkg/hr) during the first 60
minutes of reperfusion markedly improved renal function,
reduced lipid peroxidation, and produced less histologic injury
[61]. Iron-saturated deferoxamine had no protective effect.
Conversely, infusion of the iron complex EDTA-FeC13 during
reperfusion exacerbated postischemic renal dysfunction and
lipid peroxidation. These data are consistent with the notions
that the availability of transition metals such as iron favors the
generation of 0H and that the extent of lipid peroxidation is
directly related to the magnitude of this reaction.
Schneeberger et a! recently gave 100 recipients of cadaveric
kidneys either 60 mg of bovine superoxide dismutase or placebo
as intraarterial infusions for 15 minutes immediately after
reperfusion [62]. Although they could not demonstrate a differ-
ence in the outcome when all patients were considered, a
tendency favoring the use of superoxide dismutase existed
when only paired kidneys were analyzed. For example, the
frequency of anuric long-term acute renal failure was 30% in the
superoxide-dismutase-treated kidneys versus 69% with pla-
cebo. In the patients receiving superoxide dismutase, creatinine
clearance was 7.5 mllmin on day 2 versus 4.0 mi/mm in
controls, and 15.0 mllmin on day 7 versus 7.0 mi/mm in
controls. The significance values were between 0.07 and 0.1.
Additional studies are being performed using recombinant
human superoxide dismutase given by intravenous bolus prior
to reperfusion of the graft.
Calcium-channel-blocking agents
Changes in the concentration and compartmentalization of
intracellular calcium appear to be closely related to reperfusion
injury and the transition from reversible cell injury to cell death.
This topic has been the subject of several comprehensive
reviews [63—65]; I will concentrate here on recent studies
performed in renal transplant recipients. I should mention that
under normal conditions, free calcium in the cytosol of the cell
is maintained at low levels compared with that in the calcium-
rich extracellular fluid. In contrast, irreversibly injured cells
contain high levels of calcium. The extent to which these levels
rise can be correlated with the severity of the histologic
damage.
Intracellular concentration and distribution of calcium can be
altered during and following ischemia via several mechanisms.
First, with the depletion of oxygen and the fall in ATP levels,
the ability of cells to export calcium by ATP-dependent pumps
is reduced. In addition, calcium sequestration by mitochondria
and the endoplasmic reticulum is also energy-dependent, and
the cell's capacity to compensate for an influx of calcium might
be limited. Second, a significant quantity of calcium is corn-
plexed to soluble substances such as ATP, citrate, and gluta-
mate. The decrease in pH that occurs when organs are rendered
ischemic decreases the affinity of calcium for these substances
and therefore can result in the release of calcium as free ions.
Third, lipid peroxidation induced by free radicals renders cell
membranes permeable to calcium.
Table 4. Effect of diItiazem on posttranspiant renal functiona
Control Diltiazem
Number of patients 22 20
Diltiazem dose
Perfusate — 20 mg/liter
Recipient
IV bolus — 0.28 mg/kg
IV infusion — 2.2 g/kg/min (48 hrs)
Oral — 120 mg/day (7 days)
Initial nonfunction 9/22 (41%) 2/20 (10%) P < 0.05
Number hemodialyses 3.5 0.8 0.6 0.2 P < 0.05
GFRb (mi/mm), day 4 20 0.8 29 0.6 P < 0.05
day 7 24 0.7 39 1.4 P < 0.05
RBFb (mi/mm), day 4 82 3 148 8 P < 0.05
day 7 122 7 213 8 P < 0.05
a Data from Ref. 67; Results are mean SCM.b Data from kidneys with initial function only; RBF, renal blood flow;
GFR, glomerular filtration rate.
When calcium accumulates, several interrelated reactions
proceed. First, calcium activates phospholipases that remove
fatty acids from membranes and potentiate the damaging effects
of free radicals. Calcium-activated phospholipases also control
the release of arachidonic acid from the membrane and influ-
ence the production of various prostaglandins. Second, the
activation of phospholipases by calcium contributes to mito-
chondrial damage and limits the cell's capacity for ATP synthe-
sis. Third, a calcium-activated protease may favor the forma-
tion of xanthine oxidase and promote free radical formation.
Several studies of the effects of the calcium channel blocking
agent diltiazem on posttransplant function merit particular
attention [66—69]. in each study, donor kidneys were perfused
with a solution containing diltiazem; the recipients received an
intravenous infusion of diltiazem following transplantation and
later were given oral diltiazem. Wagner and colleagues exam-
ined 42 patients who received cadaveric kidney transplants
(Table 4) [67]. The control group of 22 did not receive diltiazem.
In the 20 diltiazem-treated patients, the incidence of primary
nonfunction was significantly less (10%) than in the control
group (41%). Consequently, the posttransplant requirement for
hemodialysis was substantially reduced. Even when the pa-
tients in both groups with primary nonfunction were excluded,
inulin and PAH clearances were significantly greater in the
diltiazem-treated patients than in the control patients.
Comparable results were reported by Frei and colleagues
[69]. In a prospective randomized trial, they evaluated 110
consecutive patients receiving first or second kidney trans-
plants. Fifty-four patients received diltiazem in a manner sim-
ilar to that used by Wagner; 56 patients did not receive the drug.
The incidence of initial nonfunction was 13% in the treated
group (7 of 54) and 34% in the control group (19 of 56), a
significant difference.
In both studies, immunosuppression was achieved with cy-
closporine A. Because the early use of cyclosporine increases
the probability of delayed graft function, it is not clear whether
diltiazem minimized renal ischemic injury or prevented cyclo-
sporine nephrotoxicity.
Prostaglandins
Prostacyclin (PGI2, epoprostenol) is a potent systemic vaso-
dilator. It prevents platelet aggregation and, more important for
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Table 5. Effect of ifosfamide on posttransplant renal functiona
Control Ifosfamide
Number of patients 19 16
Ifosfamide dose 0.5 mg/liter in perfusate
Initial nonfunction 9/22 (41%) 4/16 (25%) P < 0.05
Total hemodialysis
GFRb (mi/mm), day 1
34
17.1 2.1
17 P < 0.05
24.6 5.6 NS
day 4 17.4 4.8 28.8 6.5 NS
day 7 25.7 13.0 27.2 3.2 NS
RBFb (ml/min), day 1 61.0 15.4 152.2 26.7 P < 0.05
day 4 79.4 17.2 88.6 17.0 NS
day7 126.1 38.6 111.7 20.5 NS
a Data from Ref. 92. Results are mean SEM. NS, not significant.b Data from kidneys with initial function; RBF, renal blood flow.
today's discussion, it appears to have "cytoprotective" prop-
erties. Several studies in dogs and rats have demonstrated that
treatment with PGI2 can decrease the severity of postischemic
acute renal failure [70—76]. The mechanism by which PGI2
protects against ischemic renal injury has not been established,
although at least part of its salutary effect may be independent
of its vasoactive effects [76].
The mechanism by which PGI, exerts its cytoprotective
action might be related to changes in membrane transport
processes, increases in tissue levels of adenosine triphosphate
and other cyclic nucleotides [77, 781, or alterations in the
enzyme systems generating toxic free radicals [79]. The last
mechanism might involve a direct cellular action [80], or it
could result from the inhibition of oxygen-centered radical
formation from neutrophils [81—83]. Other undefined mecha-
nisms of cell preservation also might be influenced by PGI2 [84].
Finally, it is possible that other cytoprotective agents interact
with PGI2. For example, Forster reported that calcium-channel-
blocking agents stimulate PGI2 production [851.
The normal balance between the production of PGI2 and
POE2 on the one hand, and thromboxane (TxA2) on the other,
may be altered markedly during renal ischemia. An increase in
cellular calcium might activate phospholipases, which in turn
promote the release of arachidonic acid from cell membranes.
As a result of the lipid peroxidation from the action of oxygen-
free radicals, PGI2 synthesis is inhibited and TxA2 synthesis is
stimulated. Lelcuk et al proposed that the combination of an
increase in PGI2 and a decrease in TxA7 is important in
minimizing renal ischemic injury [75]. Thus, cyclooxygenase
inhibitors that block conversion of endoperoxide to both TxA2
and PGI, are not effective, whereas thromboxane synthetase
inhibitors, which not only inhibit TxA2 synthesis but also
stimulate P012 production, are beneficial. Under certain cir-
cumstances, the administration of POE1 [86—88] or PGE2 [89,
90] offers a certain degree of protection from ischemic injury in
experimental animals.
It is unfortunate that the clinical utility of P012 is limited
because of its instability at physiologic pH and temperature.
This problem has led to the use of the P012 analogue ifosfamide
(Iloprost), which has been shown to be effective in animals even
when its infusion is limited to the period of reperfusion [91]. In
a recent prospective randomized study of human renal trans-
plantation, ifosfamide (0.5 mg/liter) was added to the perfusate
of cadaveric kidneys (Table 5) [92]. Compared with the control
group, the kidneys receiving ifosfamide had a much lower
incidence of initial nonfunction, and their recipients had a
reduced number of hemodialyses and a significantly faster fall in
serum creatinine concentration for the first several days follow-
ing transplantation.
Atrial natriuretic factor
Until now I have concentrated on the effects of several
classes of agents and their ability to interrupt the cascade of
events within tubular epithelial cells that leads to irreversible
injury. I mentioned earlier, however, that we could not dismiss
the role of renal perfusion. The preliminary results of studies
using atrial natriuretic peptide lend credence to this caution.
In addition to its remarkable ability to increase salt and water
excretion [93], atrial natriuretic peptide can substantially in-
crease glomerular filtration rate under a variety of conditions
[94]. This increase has been ascribed to a rise in the glomerular
capillary ultrafiltration coefficient with an increase in the gb-
merular capillary hydrostatic pressure. The latter occurs as a
result of combined afferent arteriolar vasodilation and efferent
arteriolar vasoconstriction [95, 96].
Atrial natriuretic peptide effectively reduces the severity of
acute renal failure associated with ischemic insults [97—101].
However, the results have been poor when the injury has been
induced by nephrotoxins such as glycerol, uranyl nitrate, and
gentamicin: with such nephrotoxins, infusion of atrial natri-
uretic peptide increases GFR only during the time of the
infusion [99, 102, 103].
In the setting of postischemic acute renal failure, however,
the use of atrial naturetic peptide has led to long-term improve-
ment in renal function. Schafferhans et al produced ischemic
injury in the rat by a 40-minute infusion of norepinephrine, 0.75
pg/kg body weight, into the left renal artery [97]. Immediately
after the ischemic insult, atrial natriuretic peptide, 4 ng/g body
weight, was infused intrarenally. In response to this infusion,
the glomerular filtration rate increased from values that ap-
proached zero to values that even exceeded those prior to the
ischemic injury. By comparison, in saline-treated animals the
glomerular filtration rate returned to values that were only 30%
of control (0.29 mllmin versus 1.03 ml/min) [97]. In additional
studies, Schafferhans and colleagues infused atrial natriuretic
peptide in doses of 0.05, 0.1, or 1.0 nglg body weight per minute
for 40 minutes prior to the infusion of norepinephrine and
prevented acute renal failure [98].
In-vitro studies also support the protective effect of atrial
natriuretic peptide. In the isolated perfused kidney, when
ANP-III, 100 gId1, was given for 30 minutes after a one-hour
period of ischemia, renal plasma flow increased from 33.2
ml/min to 39.4 ml/min/g body weight, inulin clearance increased
from 24.6 to 182.6 d/min/g body weight. A prolonged effect was
observed when ANP-III, 0.20 g/kg/min for 60 minutes, was
infused after one hour of bilateral renal artery occlusion in the
rat. The inulin clearance returned to 244.5 1uilmin/100 g body
weight versus 15.8 ig/min/l00 g body weight in controls. The
serum creatinine concentration was significantly less both at 24
hours (1.8 versus 3.3 mg/dl) and 48 hours (1.0 versus 2.4 mgldl).
Moreover, during the period of reflow, P-3 1 nuclear magnetic
resonance showed a more rapid recovery of renal cortical ATP
levels at one and two hours [100].
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When alpha human atrial natriuretic peptide was given as a
4-hour intrarenal infusion following 45 to 60 minutes of renal
artery occlusion, the inulin clearance rose to 0.314 from 0.05
rnlIminIlOO g body weight, compared with a normal value of
0.49 mlIminIlOO g body weight. There was a progressive de-
crease in the degree of medullary hyperemia, and tubular cell
shedding and granulocyte margination were prevented. Histol-
ogy was essentially normal at 24 and 48 hours [1011,
Data on the effectiveness of atrial natriuretic peptide in
clinical acute renal failure are sparse. Only 6 renal transplant
recipients have received human atrial natriuretic peptide; all 6
patients were oligoanuric [1041. The infusion was given only
after 180 minutes of revascularization. Atrial natriuretic peptide
was given initially as a 100 g intravenous bolus and then as an
intravenous infusion of 600 pg over 30 minutes. A diuresis
occurred in only 2 of the patients. The nature of the study does
not allow definitive conclusions to be drawn.
To summarize, at present it is not possible to prevent
posttransplant acute renal failure. Success at minimizing isch-
ernie injury has been notable. It is hoped that these lessons can
be carried over to the more common forms of acute renal failure
observed in clinical practice.
Questions and answers
DR. Jol-IN T. HARRLNGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I always have
been intrigued as to how we know whether infused nucleotides
get to where we want them to go. Are there any tracer studies
that demonstrate where within the kidneys the nucleotides go?
There is a tremendous "black box" between the nucleotide
infusion and the outcome measures and we have no idea what is
going on in there.
DR. FINN: The phosphorylated nucleotides are not permeable
across normal cell membranes. It is quite possible that ischemic
injury to tubular epithelial cell membranes alters this barrier so
that a number of substances ordinarily excluded from the cell
gain entry. The data indicating that the infusion of ATP, ADP,
or AMP are equally effective in promoting early recovery,
rather than lessening the initial injury, suggest that the supply of
substrate for nucleotide regeneration is more important than the
delivery of a source of energy [261.
DR. HARRINGTON: You discussed several different agents
that might be useful in preventing ATN after transplantation.
Do studies combining these "potions" demonstrate any addi-
tive effects and give us any insight regarding their mechanism of
action?
Da. FINN: In general, additive effects have not been demon-
strated. Specifically, there has been no additive effect when
ATP-MgCI2 was infused with thyroid hormone, when the cal-
cium channel blocking agent diltiazem was used in conjunction
with the prostacyclin analogue ifosfamide, or when allopurinol
was combined with free-radical scavengers. However, all com-
binations have not yet been examined. Conger et al have
combined low doses of dopamine with atrial natriuretic factor
with notable success [105].
Insight into their mechanisms of action may be gained by
considering the observations that the calcium channel blocking
agents are more effective when given prior to the period of
ischemia; that xanthine oxidase inhibitors and free-radical
scavengers reduce injury when given during reperfusion; and
that the infusion of ATP-MgCl2 may be delayed for days yet still
be effective.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): To a
great extent, the various protective modalities have been tested
in ischemic acute renal failure involving native kidneys. Is there
any reason to believe that the pathophysiology or structural
component of ischemic renal failure might be different in the
transplanted kidney as compared with native kidneys?
DR. FINN: We have several reasons to believe that the
pathophysiology of ischemic acute renal failure in the trans-
planted kidney is different than that in native kidneys. The most
important of these reasons is that the transplanted kidney is
subjected to periods both of warm and cold ischemia. This does
not often happen to native kidneys. Rather, the acute renal
failure may be a consequence of prolonged hypoperfusion and
hypoxia rather than ischemia.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): What is the difference in the effect of
cold storage versus puisatile perfusion on harvested donor
kidneys and of the colloid that is used in the perfusates and
baths? Are some methods clearly superior to others?
DR. FINN: The primary aim of cold storage is to protect the
kidney during ischemia. The kidney also may be flushed with
various solutions designed to prevent cell swelling and remove
all residual blood. The advantage of hypothermic perfusion is
the ability to maintain metabolic function for a longer time.
Although a more cumbersome and expensive technique, pulsa-
tile perfusion often is preferred if the kidney has been subjected
to an extended period of warm ischemia. The addition of colloid
to the perfusate decreases the accumulation of interstitial fluid
and promotes better function. At times, pulsatile perfusion
itself can cause renal injury and be a cause of poor graft
function.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief,
New England Medical Center): Are we far enough along in this
research to recommend any particular regimen for the typical
patient undergoing transplantation now?
DR. FINN: A European multicenter clinical trial currently is
underway to test the efficacy of the preservation solution
developed at the University of Wisconsin. This solution con-
tains adenosine, glutathione, and allopurinol. Preliminary re-
suits indicate that when compared with kidneys preserved with
Euro-Collins solution, postoperative serum creatinine values
decrease more rapidly and the total number of dialyses is
reduced [1061.
DR. MADIAS: Studies have shown that following acute is-
chemic injury in native kidneys, autoregulation of renal blood
flow is markedly impaired [1071. Are there similar studies in
transplanted kidneys, and to what extent is this a concern for
recurrent ischemic injury?
DR. FINN: Severe ischemic injury is accompanied by an
increase in renal vascular resistance and a decrease in renal
blood flow. In the initial phase, the increase in renal vascular
resistance is due to parallel rises in both preglomerular and
postglomerular vascular resistances. Later, the increase in
preglomerular vascular resistance predominates. In both cases,
a reduction in perfusion pressure is accompanied by a propor-
tional decline in renal blood flow rather than by the expected
decrease in renal vascular resistance. Indeed, it is possible that
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the failure in autoregulation of renal blood flow explains the
propensity for additional injury.
It is curious that the salutory effect of atrial natriuretic
peptide is associated with a decrease in afferent arteriolar
vascular resistance and an increase in efferent arteriolar vascu-
lar resistance. Those effects combine to increase the glomerular
capillary hydrostatic pressure which, if followed by an increase
in intratubular hydrostatic pressure, may be sufficient to clear
the tubule of obstructing debris. These phenomena, in turn,
may not only promote flow through peritubular capillaries,
which would otherwise be compressed by the distended tu-
bules, but also prevent the secondary increase in preglomerular
vascular resistance that follows prolonged tubular obstruction.
DR. MADIAS: I would like to suggest yet another mechanism
through which calcium channel blockers might be helpful in
ameliorating acute renal failure. To the extent that the novel
vasoconstrictor peptide endothelin is shown to play a role in the
pathophysiology of acute ischemic renal failure, as some pre-
liminary data suggest, calcium channel blockers might provide
benefit. Nicardipine was shown to markedly attenuate endo-
thelin-induced vasoconstriction, and it has been hypothesized
that endothelin might represent an endogenous agonist of the
dihydropyridine-sensitive calcium channel [1081.
Now let me ask another question. What do you consider to be
the optimal mode of using cyclosporine in renal transplanta-
tion?
DR. FINN: The optimal use of cyclosporine has yet to be
defined. I can only describe the use at our institution. All
recipients of cadaveric renal allografts are treated with cyclos-
porine. In the initial posttransplant period, once urine flow has
been established, cyclosporine is administered as a constant
intravenous infusion at a daily dose of 2.5 mg/kg body weight
for 48 hours. Thereafter, cyclosporine is given as a single oral
dose of 10 mg/kg/day. If satisfactory plasma levels are not
obtained, the dose is divided and given every 12 hours. Over
several months, the dose is tapered to approximately 5 mg/kg
body weight. The speed of the taper depends in part on the
presence or absence of signs of systemic and/or renal toxicity;
the latter is defined by a serum creatinine concentration above
2.0 mg/dl. If required, a further reduction in the dose of
cyclosporine to 2.5 mg/kg body weight is accompanied by the
addition of azathioprine, 1 mg/kg body weight. If cyclosporine
is not tolerated at this dose, the azathioprine is increased to 2
mg/kg body weight and additional reductions in the cyclospo-
rine dose are made.
DR. HARRINGTON: The studies of diltiazem seem impressive.
Could you give us more details of those studies? Was only the
donor treated, or were the recipients treated as well, and with
what kind of doses?
DR. FINN: In the studies by Wagner et al, the donor kidneys
were perfused with Euro-Collins solution containing diltiazem
(20mg/liter). The graft recipient received intravenous diltiazem,
0.28 mg/kg, as a preoperative bolus followed by an infusion of
diltiazem, 2.2 gIkg/min for 2 days. Thereafer, oral diltiazem,
120 mg/day, was given [671. In the studies by Frei et al, the
donor kidneys were not perfused with a diltiazem solution. A
loading dose of 0.28 mg/kg was given 2 hours before surgery,
followed by a continuous infusion of 0.12 mg/kg/hr up to 72
hours after surgery. Diltiazem treatment was then continued
with an oral dose of 180 mg/day until day 30 [69].
DR. KASSIRER: Can you comment on the relationship be-
tween the acute renal failure that occurs after transplantation
and that which we see in the intensive care unit?
DR. FINN: As I previously mentioned, the transplanted
kidney is subjected to a period of complete ischemia. The
resultant injury is minimized by either simple cold storage or
hypothermic pulsatile perfusion. In the intensive care unit, the
causes of acute renal failure are more likely to be multifactorial.
Nevertheless, certain parallels exist. For example, following
transplantation, the use of cyclosporine exposes the previously
ischemic kidney to a potential nephrotoxin. This may be
somewhat comparable to the treatment of gram-negative shock
with aminoglycoside antibiotics in the setting of the intensive
care unit. A greater understanding of the additive effects of
renal ischemic injury and nephrotoxic agents is likely to benefit
both populations of patients.
Dg. MADIAS: From the human data that are currently avail-
able, is there any evidence that it makes a difference in the long
term whether the patient is treated with one of these protective
maneuvers?
DR. FINN: In the studies by Wagner et al, the GFR of those
grafts with primary function was significantly higher on days 4
and 7 in the diltiazem-treated group compared with controls
(day 4: 29 0.6 versus 20 0.8 ml/min; day 7: 39 1.4
versus 24 0.7 mllmin; P < 0.05) [67]. In the studies by Frei et
al, although there was a significantly lower incidence of initial
graft nonfunction in the diltiazem-treated group compared with
the control group, serum creatinine levels after 1, 3, 6, and 12
months did not differ significantly in both groups [69].
Reprint requests to Dr. W. Finn, Division of Nephrology, University
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